Prognosis Analysis of Patients with Pancreatic Neuroendocrine Tumors After Surgical Resection and the Application of Enucleation.

Junzhang Chen
Southern Medical University First Affiliated Hospital: Southern Medical University Nanfang Hospital

Yongyu Yang
Southern Medical University Nanfang Hospital

Yuanhua Liu
Southern Medical University Nanfang Hospital

Heping Kan (ḡdw_nfyy123@163.com)
Southern Medical University Nanfang Hospital

Research

Keywords: Pancreatic neuroendocrine tumor (pNETs), Surveillance, Epidemiology, and End Results (SEER) database, Surgical resection, Prognostic factor, Enucleation

DOI: https://doi.org/10.21203/rs.3.rs-98578/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective: To investigate the prognostic factors of patients with pancreatic neuroendocrine tumor (pNENs) after surgical resection, and to analyze the value of enucleation for pNETs without distant metastasis that are well-differentiated (G1) and have a diameter ≤ 4 cm.

Methods: Data from pNET patients undergoing surgical resection between 2004 and 2017 were collected from the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan–Meier analysis and log-rank testing were used for the survival comparisons. Adjusted HRs with 95% CIs were calculated using univariate and multivariate Cox regression models to estimate the prognostic factors. P < .05 was regarded as statistically significant.

Results: This study found that female, cases diagnosed after 2010, and pancreatic body/tail tumors were protective factors for good survival while histological grade G3, a larger tumor size, distant metastasis, AJCC 8th Stage III-IV and age over 60 were independent prognostic factors for a worse OS/CSS. For the pNETs that were well-differentiated (G1) and had a tumor diameter ≤ 4 cm, the type of surgery was an independent factor for the long-term prognosis of this group. Compared with pancreaticoduodenectomy and total pancreatectomy, patients who were accepted enucleation had better OS/CSS.

Conclusion: For pNETs patients undergoing surgical resection, sex, year of diagnosis, tumor location, pathological grade, tumor size, distant metastasis, race, and age were independent prognostic factors associated with the OS/CSS of patients. For pNETs patients with G1 and a tumor diameter less than 4 cm, if the tumor is located over 3 mm from the pancreatic duct, enucleation may be a wise choice.

Introduction

Neuroendocrine tumors (NETs) are rare tumors that generally originate from neuroendocrine cells in various organs, and the pancreas is one of the most common sites of NETs[1,2]. Pancreatic neuroendocrine tumors (pNETs) constitute approximately about 3-5% of the total number of pancreatic tumors, and these tumors exhibit high heterogeneity. Compared with pancreatic adenocarcinomas, pNETs are relatively slow growing but have the potential to be malignant and develop distant metastases, most commonly in the liver[3]. In recent years, the incidence of pNETs in the population has shown a continuous upward tendency. Based on whether the tumors can secrete hormones to trigger clinical symptoms, they are divided into two types of tumors, functioning or nonfunctioning tumors. Functioning pNETs generally produce one or more biologically active peptides, such as insulin, somatostatin, gastrin, or glucagon, inducing specific clinical symptoms. They account for 30% of all pNETs[4]. Nonfunctioning tumors remain asymptomatic in the early stages and are often only detected at a late stage. Many findings have suggested that patients with non-functioning tumors have a worse prognosis[2,5,6]. At present, many studies have researched the prognostic factors of pNETs both domestically and abroad. However, there are still many limitations and controversies about the prognostic factors of this disease[6-8]. There are few large databases exclusively researching the prognostic factors of pNET patients.
nonradical surgical resection. Surgery is the only treatment that can cure the disease. While pancreatic surgery is quite difficult, and there is a high risk of complications during and after surgery, pancreatic neuroendocrine tumors exhibit great heterogeneity[2]. These differences and lack of prognostic factors makes the choice of surgical procedure for pNETs more controversial. pNETs’ operations can be divided into two categories: one is tissue-sparing resection, such as enucleation and middle segmental pancreatic resection; the other is regular pancreatectomy (standard pancreatic resection), generally including pancreaticoduodenectomy, partial pancreatectomy and total pancreatectomy. A few studies have shown that compared to the other operations, The procedure of enucleation is simpler, has a shorter operation time, fewer postoperative complications, and the patients recover faster after surgery[9-11]. It is now generally accepted that the indications for enucleation are: diameter of the tumor < 2 cm and the tumor is at least 3 cm away from the main pancreatic duct. However, there is limited research to support surgical decisions. This paper retrospectively analyzed the 2751 pNETs cases of radical or nonradical surgical resection that were collected from 2004 to 2017, using SEER data, to study the prognostic factors of these patients undergoing surgical resection. Another important aspect of the study was to explore the long-term efficacy of enucleation in pNET patients with pathological grade G1 and a tumor diameter ≤ 4 cm.

Materials And Methods

Data source

The case data were derived from the SEER database of the National Cancer Institute of the United States, using SEER∗stat software (version 8.3.6), and the reference number was 11706-Nov2019. This database covers approximately 30.0% of cancer cases in the U.S. population and provides clinical workers with first-hand data about cancer epidemiology, clinical features, treatment information, and outcomes[12]. All of the pNETs cases were diagnosed from 2004 to 2017. This study was approved by the Institutional Review Board.

Inclusion and Exclusion Criteria

The inclusion criteria were: 1, Pancreatic neuroendocrine tumor was the only primary tumor. 2, pancreatic anatomical sites were included (C25.0–C25.8) in our study. 3, ICD-O-3 (International Classification of Diseases for Oncology, 3rd edition) morphology codes 8150-8153, 8155-8157, 8240-8243, and 8246, 8249 were selected, and then 5240 pNET patients were collected from the SEER database.

The exclusion criteria are described below, and shown in Figure1.

1. Cases with missing data (n=2669)

(I) Unknown histological grade (n=1709)

(II) No surgical resection was performed and surgical type was uncertain (n=874)
(III) Unknown stage of aggression (n=29)

(IV) Unknown tumor size (n=16)

(V) Unknown race (n=30)

Cases with survival ≤ 1 month (n=11);

After exclusion, a total of 2571 patients were included. Variables included in the study had sex, year of diagnosis, age, race, tumor size, histological grade, AJCC 8th stage, type of surgery, distant metastasis, lymph node metastasis, type of tumor, and location of the tumor. There are a few data limitations in the SEER database, such as which histological methods were used for grading. In this study, well-differentiated was classified as G1; Moderated-differentiated was classified as G2; poorly differentiated and undifferentiated were classified as G3. Based on the tumor size, lymph nodes, and distant metastasis, the 2571 patients were restaged using the AJCC 8th Stage standards. Overall survival was censored according to the vital status of patients. Cancer-specific survival was based on “cancer-specific death”.

**Statistical analysis**

Univariate and multivariate Cox proportional hazard analysis was used to identify the factors that were independently associated with CSS and OS. Variables with P ≤ 0.1 on univariate analysis were further included in the multivariate analysis. The Kaplan–Meier analysis with the Log-rank test was used to describe the CSS and OS. All tests were two-sided, P<0.05 was considered as statistically significant. All statistical analyses were performed using IBM SPSS Statistics version 24.0, and survival curves were drawn with GraphPad Prism 8.0.1.

**Result**

**Baseline characteristics of the patients**

After screening against the exclusion criteria, 2571 patients were included in the study. The detailed clinical characteristics of the patients are shown in Table 1. Male patients accounted for 51.8% of the total. A marked increase in the number of pNETs cases after 2010 was seen, accounting for 85% of the total number of cases. Approximately 14.6% of the patients had metastasis before surgical resection, and 16.6% of the patients had no lymph node dissection during the operation. The number of white people accepting surgery was much higher than that of the other races.

**Survival outcomes**

Table 2 showed that the log-rank test was used to analyze the factors associated with CSS and OS in 2751 pNETs cases. It can be seen that except for the type of tumor, sex, year of diagnosis, tumor location, pathological grade, preoperative distant metastasis, tumor size, AJCC stage, lymph node metastasis, race
and age were associated with the OS. Race was a prognostic factor for OS but not CSS. The CSS of the patients were related to sex, year of diagnosis, tumor location, pathological grade, preoperative distant metastasis, tumor size, AJCC stage, lymph node metastasis, and age. The 5-year OS was 85.6% for all cases, the 5-year CSS was 88.6%, and the median survival time was not obtained. A few median survival times of subgroups were obtained. The MST of G3 was 40m, the patients with distant metastasis was 87 m, the diameter of the tumor over 4 cm was 137m, the AJCC 8th Stage III-IV was 145 m, and age over 60 years was 145 m.

The confirmation of independent prognosis factors

Tables 3 and 4 show the univariate and multivariable regression analysis results. The variables p<0.1 in Cox univariate analysis were further analyzed using multivariate analysis. The results showed that female patients, diagnosed after 2010, and tumors of the pancreatic body and tail had better long-term survival. If the pathological grade was G3, there was distant metastasis, the diameter of the tumor was larger, AJCC 8th Stage III-IV, the white race and older age were associated with worse OS/CSS. Sex, year of diagnosis, location of the tumor, histological grade, distant metastasis, tumor size, AJCC 8th Stage, race, and age were the independent prognostic factors for pNET patients undergoing surgical resection.

The evaluation of enucleation in pNETs

Figure 2 shows the survival curve among different surgical modalities for pNETs with ≤4 cm and G1, including OS and CSS, drawn by GraphPad Prism. Both of them P value<0.05. Table 6 shows the multivariate Cox proportional hazard model analyzing long-term prognosis among different operations. The clinical variables brought into the analysis were independent prognosis factors for pNET patients accepted surgical treatment, including sex, year of diagnosis, tumor location, AJCC 8th Stage, race, and age. It can be seen that for pNETs with G1, diameter≤4 cm, the mode of surgery is an independent factor for their long-term prognosis. Compared with enucleation, patients who received total pancreatectomy or pancreaticoduodenectomy had worse OS and CSS. The long-term survival of 273 pNETs with G2 and diameter ≤ 4 cm was analyzed by univariate regression analyses. The p value was over 0.1, so it could not be further analyzed by a multivariate Cox proportional hazard model. the OS and CSS of patients with partial pancreatic resection seemed to be better than for other procedures (Figure 3).

Discussion

The pNET patient data were collected from the SEER database of the National Cancer Institute of the United States. After screening against the inclusion and exclusion criteria, 2571 pNET patients were selected. Different from other studies that analyzed the prognostic factors of pNET patients, this study was specific to pNET patients undergoing surgical resection to explore the relevant factors affecting the prognosis of these patients, increasing the clinical evidence for this rare disease. Another important aspect of this study was to clarify the application value of enucleation for pNETs which might promote the development of pNETs surgical treatment.
First, as we can see from Table 2, the results of log-rank analysis showed that, except for the type of tumor, sex, year of diagnosis, tumor location, pathological grade, distant metastasis, tumor size, AJCC 8th stage, lymph node metastasis, and patient's age were all significantly associated with OS and CSS. Ethnicity was associated with patient OS but not CSS. In Tables 3 and 4, Cox multivariate analysis showed that women, diagnosed after 2010, and pancreatic body/tail tumor were independent protective factors for the long-term survival of pNET patients undergoing surgical resection, although the reason why women had a better OS/CSS was not clear.

Patients diagnosed after 2010 can receive better medical technical support. Surgical resection of the pancreatic body/tail is simpler than that of the pancreatic head. The former does not require the removal of a portion of the stomach and duodenum[13]. Patients may be more willing to undergo surgery without needing higher risk pancreaticoduodenectomy.

pNET patients with G3, distant metastasis, larger tumor diameter, AJCC 8th III-IV stage, the white race or age ≥60 years old were associated with a worse OS/CSS. A higher pathological grade and lower differentiation of tumor cells indicate the tumor may be more malignant[14,15], pNET patients with distant metastasis are difficult to treat since the removal of the primary and metastatic tumors may be impossible, and most of them can only achieve R1 or R2 resection[8]. Their prognosis is poorer than patients with an R0 resection. Some studies have shown that tumor size is not associated with the long-term prognosis of patients[1,16]. However, this study found that tumor diameter was an independent factor affecting the OS/CSS of patients. A larger tumor may increase the difficulty of the operation, which also indicates that the tumor has existed for a long time, which increases the risk of distant metastasis of tumor cells. AJCC 8th staging is the latest pNETs staging method and its practicability has been widely recognized, and later staging means patients may have a poor prognosis[17]. Elderly patients are generally in poor health and more likely to have chronic diseases or perioperative complications, and consequently, older pNET patients have a worse prognosis. Although some studies suggested that race was an independent prognostic factor in pNETs, the overall prognosis of blacks was worse than the white race, which may be related to economic and social status[16,18]. Among patients who had received surgical resection, the long-term prognosis between blacks and whites were not significant difference in this study, and white people had worse OS/CSS than that of other race such as Asian American. Many studies suggested that preoperative lymph node metastasis is associated with the long-term prognosis in pNET patients[19,20], while others have not found a significant connection[21,22]. In this study, Cox multivariate analysis suggested that lymph node metastasis could not be used as an independent prognostic factor for postoperative patients. lymph node ratio (LNR) may be more persuasive as a prognostic factor than simply assessing the presence or absence of lymph node metastasis[23], but the specific mechanism needs to be supported by more multiple-center and large clinical database studies in the future. Comparing functional with nonfunctional tumors, the present clinical consensus is that nonfunctional tumors have a worse prognosis than functional tumors due to lack of clinical symptoms in the early stage. NF-pNETs are generally found at a later stage. However, with the progress in examination technology and the popularization of routine physical examinations, the influence of different tumor types on survival prognosis remains to be discussed. This study showed that there was no significant
difference between functional and nonfunctional tumors for OS/CSS. It might be that the SEER database classified many early stage F-PNETs tumors as benign lesions and did not include them in the database, which affected the final statistical results. Another reason could be only pNET patients undergoing surgical resection were included in this study, and there may be no significant difference in the long-term prognosis between postoperative F-PNET and NF-PNET patients.

Current surgical principles consider that enucleation is only suitable for tumors less than 2 cm in diameter and the distance between the tumor and main pancreatic duct needs to be over 3 mm[11]. However, this point has not been verified by multiple-center and large clinical databases, and the research using small sample data is also scarce. The application value of enucleation for pNETs still needs to be determined. This study specifically analyzed the value of enucleation for well and moderately-differentiated pNETs with a diameter ≤4 cm. As shown in Table 6, pNETs with G1 and diameter ≤4 cm who received pancreaticoduodenectomy or total pancreatectomy had a worse OS/CSS than those undergoing enucleation. This may be the result of the higher risk of these two procedures and the higher probability of postoperative complications. On the other hand, well-differentiated pNETs have lower pNETs malignant potential[14], which can greatly increase the possibility of achieving a complete radical resection. There was no significant difference in OS/CSS between partial pancreatic resection and enucleation. However, some studies have confirmed that the procedure of enucleation is a relatively simple, short operation, with less trauma to the patients and a shorter postoperative hospitalization time[10, 24]. Therefore, in general, for well-differentiated, and diameter ≤4 cm pNET patients without distant metastasis, enucleation seems to be more sensible in cases of radical resection. Table 7 shows long-term survival curves of G2 pNET patients with a tumor diameter ≤4 cm. There was no statistical significance between groups in univariate Cox regression analysis. The primary cause of this may be the insufficient number of cases. Compared to G1 cases, the total number of G2 pNET patients with a diameter ≤4 cm included in the study was 273, and among them, only 23 patients were enucleated. Total pancreatectomy was performed in only 13 cases. The trend of the K-M survival curves suggests that enucleation has no significant advantage in long-term outcomes among G2 tumors and that patients receiving partial pancreatectomy seem to have better OS and CSS. However, more relevant studies are needed to prove this.

This present study has certain limitations. Firstly, it was retrospective study which could exist selection bias. Secondly, as a population-based registry, the SEER database has not provided some detail information, such as the recurrence of p-NETs after surgery resection, postoperative complications, surgical margin status, and additional adjuvant therapy (chemotherapy, targeted or endocrine therapy). Furthermore, the SEER database could not absolutely avoid coding errors due to extensive collection of cases data from different regions. Despite the existence of above limitations, our research still produced important clinical values.

**Conclusion**
This study has demonstrated the independent prognostic factors of pNET patients after surgical resection, including sex, year of diagnosis, location of the tumor, pathological grade, tumor size, distant metastasis, race, and age. The study found that for G1 pNET patients with a tumor diameter ≤4 cm, enucleation seems to be a better surgical protocol if the distance between the tumor and the main pancreatic duct is over 3 mm.

**Declarations**

**Acknowledgements**

No applicable.

**Authors’ contributions:**

J.Z.C., Y.Y.Y., and Y.H.L participated in the conception and design of this project, interpretation of data, and drafting. J.Z.C. collected data and analysis. H.P.K gave critical revision of the article and final approval of the manuscript to be submitted.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

The datasets analyzed of this study are collected from SEER repository (https://seer.cancer.gov/).

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Disclosure**

The authors reported that they have no conflict of interests.

**References**

1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA ONCOL. 2017 2017-01-01;3(10):1335-42.
2. Guilmette JM, Nose V. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. ADV ANAT PATHOL. [Journal Article; Review]. 2019 2019-01-01;26(1):13-30.

3. Dong DH, Zhang XF, Poultsides G, Rocha F, Weber S, Fields R, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases. J SURG ONCOL. 2019;120(7):1071-9.

4. Raj N, Reidy-Lagunes D. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematology/Oncology Clinics of North America. 2016;30(1):119-33.

5. Wang S, Zhang J, Liu S, Zhang J. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients. MEDICINE. 2019;98(44):e17773.

6. Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. SURG CLIN N AM. 2019;99(4):793-814.

7. Zhou RQ, Ji HC, Liu Q, Zhu CY, Liu R. Leveraging machine learning techniques for predicting pancreatic neuroendocrine tumor grades using biochemical and tumor markers. WORLD J CLIN CASES. [Journal Article]. 2019 2019-07-06;7(13):1611-22.

8. Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment Options for Pancreatic Neuroendocrine Tumors. CANCERS. 2019 2019-06-14;11(6):828.

9. Hackert T, Hinz U, Fritz S, Strobel O, Schneider L, Hartwig W, et al. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbeck's Archives of Surgery. 2011;396(8):1197-203.

10. Cauley CE, Pitt HA, Ziegler KM, Nakeeb A, Schmidt CM, Zyromski NJ, et al. Pancreatic Enucleation: Improved Outcomes Compared to Resection. J GASTROINTEST SURG. 2012;16(7):1347-53.

11. Hain E, Sindayigaya R, Fawaz J, Gharios J, Bouteloup G, Soyer P, et al. Surgical management of pancreatic neuroendocrine tumors: an introduction. EXPERT REV ANTICANC. 2019 2019-01-01;19(12):1089-100.

12. Dong DH, Zhang XF, Poultsides G, Rocha F, Weber S, Fields R, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases. J SURG ONCOL. 2019;120(7):1071-9.

13. Doi R. Determinants of surgical resection for pancreatic neuroendocrine tumors. J HEPATO-BIL-PAN SCI. 2015 2015-08-01;22(8):610-7.

14. Gao S, Huang C, Huang X, Chen L, Chen W, Cai J, et al. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors. PANCREAS. 2019;48(6):795-8.

15. Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K, Miyasaka Y, et al. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. Cancer Med. [Journal Article]. 2019 2019-07-01;8(8):3748-60.

16. Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, et al. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study. Cancer medicine (Malden, MA). 2017 2017-01-01;6(11):2745-56.
17. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 2011-08-01;29(22):3044-9.

18. Zhou H, Zhang Y, Song Y, Tan W, Qiu Z, Li S, et al. Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database. CLIN RES HEPATOL GAS. 2017;41(4):476-86.

19. Sahara K, Tsilimigras DI, Mehta R, Moro A, Paredes AZ, Lopez-Aguiar AG, et al. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. ANN SURG ONCOL. 2020;27(4):1203-12.

20. Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. EXPERT REV ANTICANC. 2019 2019-01-01;19(12):1029-50.

21. Tan Q, Wang X, Yang L, Chen Y, Tan C, Zhu X, et al. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. MEDICINE. 2020 2020-06-12;99(24):e20324.

22. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. ANN SURG. [Journal Article; Research Support, Non-U.S. Gov't]. 2008 2008-03-01;247(3):490-500.

23. Gaitanidis A, Patel D, Nilubol N, Tirosh A, Kebebew E. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. [Journal Article; Research Support, N.I.H., Intramural]. 2018 2018-01-01;103(1):187-95.

24. Dalla Valle R, Cremaschi E, Lamecchi L, Guerini F, Rosso E, Iaria M. Open and minimally invasive pancreatic neoplasms enucleation: a systematic review. Surgical Endoscopy. 2019;33(10):3192-9.

Tables
Table 1  
baseline characteristics of p-NET patients with radical or non-radical resection.

| Characteristics              | n   | %    |
|------------------------------|-----|------|
| Gender                       |     |      |
| Male                         | 1332| 51.8 |
| Female                       | 1239| 48.2 |
| Year Of Diagnosis            |     |      |
| 2004-2009                    | 379 | 14.7 |
| 2010-2017                    | 2192| 85.3 |
| Location Of Tumor            |     |      |
| Head of pancreas             | 823 | 32.0 |
| Body/tail of pancreas        | 1486| 57.8 |
| Other*                       | 262 | 10.2 |
| Type Of Tumor                |     |      |
| Functional                   | 200 | 7.8  |
| Non-functional               | 2371| 92.2 |
| Histological grade           |     |      |
| G1                           | 1915| 74.5 |
| G2                           | 511 | 19.9 |
| G3                           | 145 | 5.6  |
| Distant Metastasis           |     |      |
| No                           | 2196| 85.4 |
| Yes                          | 375 | 14.6 |
| Tumor Size                   |     |      |
| ≤2cm                         | 951 | 37.0 |
| 2-4cm                        | 920 | 35.8 |
| >4cm                         | 700 | 27.2 |
| AJCC 8th Stage                |     |      |
| I-II                         | 1098| 42.7 |
| III-HV                       | 1103| 42.9 |
|                             | 367 | 14.4 |
|                          | Yes  | 28.8 | 740  |
|--------------------------|------|------|------|
| Lymph Node Metastasis    | NO   | 54.6 | 1405 |
|                          | Untested† |     | 426  |
| Race                     | White| 76.7 | 1971 |
|                          | Black| 12.3 | 316  |
|                          | Other‡| 11.0 | 284  |
| Age At Diagnosis(yr)     | ≤60  | 61.6 | 1583 |
|                          | >60  | 38.4 | 988  |

* Overlapping lesion of pancreas/Pancreatic duct, other specified parts of pancreas.
† No lymph nodes were detected during surgery.
‡ Asian/American Indian/Alaska Native/Pacific Islander.
Table 2
The calculation of survival time using Kaplan–Meier curves and Log-rank test.

| Characteristics                | 5 years OS<%> | P     | Median Survival Time<month> | 5 years CSS<%> | P     |
|--------------------------------|--------------|-------|-----------------------------|----------------|-------|
| Gender                         |              | 0.001 |                             |                | 0.020 |
| Male                           | 82.6         | N/A   |                             | 86.9           |       |
| Female                         | 88.6         | N/A   |                             | 90.9           |       |
| Year Of Diagnosis              |              | 0.000 |                             |                | 0.000 |
| 2004-2009                      | 77.4         | N/A   |                             | 80.1           |       |
| 2010-2017                      | 88.0         | N/A   |                             | 91.2           |       |
| Location Of Tumor              |              | 0.000 |                             |                | 0.001 |
| Head of pancreas               | 82.9         | N/A   |                             | 86.3           |       |
| Body/tail of pancreas          | 88.3         | N/A   |                             | 91.0           |       |
| Other                          | 79.9         | N/A   |                             | 83.5           |       |
| Type Of Tumor                  |              | 0.240 |                             |                | 0.182 |
| Functional                     | 81.4         | N/A   |                             | 85.7           |       |
| Non-functional                 | 86.1         | N/A   |                             | 89.0           |       |
| Histological grade             |              | 0.000 |                             |                | 0.000 |
| G1                             | 89.2         | N/A   |                             | 92.3           |       |
| G2                             | 84.3         | N/A   |                             | 87.3           |       |
| G3                             | 46.1         | 40    |                             | 47.6           |       |
| Distant Metastasis             |              | 0.000 |                             |                | 0.000 |
| No                             | 90.1         | N/A   |                             | 93.5           |       |
| Yes                            | 64.1         | 87    |                             | 65.5           |       |
| Tumor Size                     |              | 0.000 |                             |                | 0.000 |
| ≤2cm                           | 93.6         | N/A   |                             | 96.7           |       |
| 2-4cm                          | 83.2         | N/A   |                             | 86.4           |       |
| >4cm                           | 79.5         | 137   |                             | 82.2           |       |
| AJCC 8th Stage                 |              | 0.000 |                             |                | 0.000 |
| I-II                           | 93.7         | N/A   |                             | 96.9           |       |
| Race          | 85.0 | 87.1 | 88.2 | 88.0 | 90.1 | 91.1 |
|--------------|------|------|------|------|------|------|
| White        |      |      |      |      |      |      |
| Black        |      |      |      |      |      |      |
| Other        |      |      |      |      |      |      |

* Overlapping lesion of pancreas
† Pancreatic duct, other specified parts of pancreas.
‡ No lymph nodes were detected during surgery.
§ Asian/American Indian/Alaska Native/Pacific Islander.
### Table 3

Univariate and Multivariable cox proportional hazards regression model for OS in 2751 p-NET patients.

| Characteristics             | Univariate analysis | Multivariate analysis |
|-----------------------------|---------------------|-----------------------|
|                             | Hazard ratio \(95\%CI\) | P       | Hazard ratio \(95\%CI\) | P       |
| **Gender**                  |                     |         |                     |         |
| Male                        | 1 [reference]       |         | 1 [reference]       |         |
| Female                      | 0.690 [0.554-0.861] | 0.001   | 0.692 [0.553-0.867] | 0.001   |
| **Year Of Diagnosis**       |                     |         |                     |         |
| 2004-2009                   | 1 [reference]       |         | 1 [reference]       |         |
| 2010-2017                   | 0.502 [0.393-0.642] | 0.000   | 0.715 [0.558-0.916] | 0.008   |
| **Location Of Tumor**       |                     |         |                     |         |
| Head of pancreas            | 1 [reference]       |         | 1 [reference]       |         |
| Body/tail of pancreas       | 0.638 [0.506-0.806] | 0.000   | 0.651 [0.510-0.830] | 0.001   |
| Other                       | 0.928 [0.659-1.307] | 0.670   | 0.992 [0.696-1.413] | 0.965   |
| **Type Of Tumor**           |                     |         |                     |         |
| Functional                  | 1 [reference]       |         |                     |         |
| Non-functional              | 0.829 [0.606-1.134] | 0.241   |                     |         |
| **Histological grade**      |                     |         |                     |         |
| G1                          | 1 [reference]       |         | 1 [reference]       |         |
| G2                          | 1.504 [1.138-1.988] | 0.004   | 1.145 [0.861-1.522] | 0.352   |
| G3                          | 7.033 [5.392-9.173] | 0.000   | 3.949 [2.977-5.240] | 0.000   |
| **Distant Metastasis**      |                     |         |                     |         |
| No                          | 1 [reference]       |         | 1 [reference]       |         |
| Yes                         | 3.992 [3.206-4.970] | 0.000   | 2.116 [1.628-2.751] | 0.000   |
| **Tumor Size**              |                     |         |                     |         |
| \(\leq 2\) cm              | 1 [reference]       |         | 1 [reference]       |         |
| 2-4cm                       | 2.451 [1.759-3.416] | 0.000   | 1.452 [1.018-2.071] | 0.039   |
| \(>4\) cm                  | 3.500 [2.526-4.850] | 0.000   | 1.517 [1.055-2.183] | 0.025   |
| **AJCC 8th Stage**          |                     |         |                     |         |
| I-II                        | 1 [reference]       |         | 1 [reference]       |         |
| III-IV                      | 3.780 [2.834-5.043] | 0.000   | 1.644 [1.091-2.476] | 0.017   |
|                | Hazard Ratio | 95% CI       | P-value | Reference Hazard Ratio | Hazard Ratio | 95% CI       | P-value |
|----------------|-------------|-------------|---------|------------------------|-------------|-------------|---------|
| Unknown        | 1.058       | 0.635-1.760 | 0.829   | 0.671                  | 0.333-1.351 | 0.264       |
| Lymph Node Metastasis |            |             |         |                        |             |             |         |
| Yes            | 1 [reference] |            |         | 1 [reference]          |             |             |         |
| NO             | 0.387       | 0.304-0.492 | 0.000   | 0.908                  | 0.664-1.241 | 0.544       |
| Not Examined   | 0.540       | 0.390-0.747 | 0.000   | 1.635                  | 1.067-2.507 | 0.024       |
| Race           |             |             |         |                        |             |             |         |
| White          | 1 [reference] |            |         | 1 [reference]          |             |             |         |
| Black          | 0.959       | 0.686-1.342 | 0.809   | 1.160                  | 0.825-1.630 | 0.394       |
| Other          | 0.545       | 0.346-0.859 | 0.009   | 0.583                  | 0.368-0.924 | 0.022       |
| Age At Diagnosis(yr) |          |             |         |                        |             |             |         |
| ≤60            | 1 [reference] |            |         | 1 [reference]          |             |             |         |
| >60            | 1.583       | 1.272-1.969 | 0.000   | 1.550                  | 1.239-1.938 | 0.000       |

Univariate analysis of variables with P < 0.1 then further analysis by multivariate cox regression model.

* Overlapping lesion of pancreas:
† Pancreatic duct, other specified parts of pancreas.
‡ Pancreas.
† No lymph nodes were detected during surgery.
‡ Asian/American Indian/Alaska Native/Pacific Islander.
Table 4
Univariate and Multivariable cox proportional hazards regression model for CSS in 2751 p-NET patients.

| Characteristics          | Univariate analysis |          |          |          |          | Multivariate analysis |
|--------------------------|---------------------|----------|----------|----------|----------|-----------------------|
|                          | Hazard ratio | 95%CI    | P        | Hazard ratio | 95%CI    | P        |
| Gender                   |          |          |          |          |          |          |
| Male                     | 1         | reference |          |          | 1         | reference |          |
| Female                   | 0.746     | 0.582-0.955 | 0.020   |          | 0.745     | 0.578-0.960 | 0.023   |
| Year Of Diagnosis        |          |          |          |          |          |          |
| 2004-2009                | 1         | reference |          |          | 1         | reference |          |
| 2010-2017                | 0.411     | 0.313-0.540 | 0.001   |          | 0.640     | 0.487-0.842 | 0.001   |
| Location Of Tumor        |          |          |          |          |          |          |
| Head of pancreas         | 1         | reference |          |          | 1         | reference |          |
| Body/tail of pancreas    | 0.609     | 0.468-0.792 | 0.000   |          | 0.624     | 0.472-0.823 | 0.001   |
| Other                    | 0.948     | 0.648-1.388 | 0.785   |          | 1.026     | 0.690-1.525 | 0.900   |
| Type Of Tumor            |          |          |          |          |          |          |
| Functional               | 1         | reference |          |          | 1         | reference |          |
| Non-functional           | 0.789     | 0.556-1.119 | 0.183   |          |          |          |
| Histological grade       |          |          |          |          |          |          |
| G1                       | 1         | reference |          |          | 1         | reference |          |
| G2                       | 1.729     | 1.264-2.367 | 0.000   |          | 1.230     | 0.893-1.693 | 0.204   |
| G3                       | 8.962     | 6.707-11.975 | 0.000   |          | 4.540     | 3.337-6.177 | 0.000   |
| Distant Metastasis       |          |          |          |          |          |          |
| No                       | 1         | reference |          |          | 1         | reference |          |
| Yes                      | 5.504     | 4.308-7.032 | 0.000   |          | 2.536     | 1.899-3.387 | 0.000   |
| Tumor Size               |          |          |          |          |          |          |
| ≤2cm                     | 1         | reference |          |          | 1         | reference |          |
| 2-4cm                    | 3.199     | 2.116-4.836 | 0.000   |          | 1.646     | 1.060-2.555 | 0.026   |
| ≥4cm                     | 4.895     | 3.265-7.337 | 0.000   |          | 1.711     | 1.096-2.672 | 0.018   |
| AJCC 8th Stage           |          |          |          |          |          |          |
| I-II                     | 1         | reference |          |          | 1         | reference |          |
| III-IV                   | 6.158     | 4.200-9.029 | 0.000   |          | 1.956     | 1.167-3.278 | 0.011   |
| Unknown       | 1.307 (0.682-2.505) | 0.420 | 0.685 (0.298-1.572) | 0.372 |
|---------------|---------------------|-------|---------------------|-------|
| **Lymph Node Metastasis** |                     |       |                     |       |
| Yes           | 1 (reference)       |       | 1 (reference)       |       |
| NO            | 0.275 (0.206-0.366) | 0.000 | 0.798 (0.551-1.131) | 0.197 |
| Not Examined  | 0.508 (0.356-0.725) | 0.000 | 1.769 (1.138-2.750) | 0.011 |
| **Race**      |                     |       |                     |       |
| White         | 1 (reference)       |       | 1 (reference)       |       |
| Black         | 0.938 (0.640-1.375) | 0.742 | 1.132 (0.767-1.670) | 0.533 |
| Other         | 0.554 (0.333-0.922) | 0.023 | 0.573 (0.342-0.962) | 0.035 |
| **Age At Diagnosis (yr)** |           |       |                     |       |
| ≤ 60          | 1 (reference)       |       | 1 (reference)       |       |
| > 60          | 1.439 (1.123-1.844) | 0.004 | 1.395 (1.081-1.801) | 0.011 |

Univariate analysis of variables with P < 0.1 then further analysis by multivariate cox regression model.

* Overlapping lesion of pancreas: Pancreatic duct, other specified parts of pancreas.
† No lymph nodes were detected during surgery.
‡ Asian/American Indian/Alaska Native/Pacific Islander.
Table 5
The Multivariable Cox proportional hazards regression model was applied to investigate the roles of different surgery on OS/CSS for G1 p-NETs with diameter ≤ 4cm.

| Characteristics          | Multivariate analysis (OS) | P     | Multivariate analysis (CSS) | P     |
|--------------------------|----------------------------|-------|----------------------------|-------|
| N=1387                   | Hazard ratio 95%CI         |       | Hazard ratio 95%CI          |       |
| **Gender**               |                            |       |                            |       |
| Male                     | 685                        | 1     | reference                  | 1     |
| Female                   | 702                        | 0.635 (0.403-1.001) | 0.050 | 0.844 (0.470-1.516) | 0.570 |
| **Year Of Diagnosis**    |                            |       |                            |       |
| 2004-2009                | 126                        | 1     | reference                  | 1     |
| 2010-2017                | 1261                       | 1.697 (0.868-3.316) | 0.122 | 1.376 (0.591-3.203) | 0.460 |
| **Location Of Tumor**    |                            |       |                            |       |
| Head of pancreas         | 406                        | 1     | reference                  | 1     |
| Body/tail of pancreas    | 854                        | 0.479 (0.260-0.881) | 0.018 | 0.502 (0.213-1.187) | 0.117 |
| Other                    | 127                        | 0.880 (0.397-1.952) | 0.753 | 1.082 (0.376-3.111) | 0.884 |
| **Surgery**              |                            |       |                            |       |
| Enucleation              | 129                        | 1     | reference                  | 1     |
| Partial pancreatectomy   | 938                        | 3.254 (0.747-14.176) | 0.116 | 3.246 (0.403-26.158) | 0.269 |
| Pancreaticoduodenectomy  | 235                        | 4.945 (1.080-22.637) | 0.039 | 10.641 (1.270-89.181) | 0.029 |
| Total pancreatectomy     | 85                         | 5.862 (1.210-28.396) | 0.028 | 10.310 (1.164-91.352) | 0.036 |
| **AJCC 8th Stage**       |                            |       |                            |       |
| I                        | 505                        | 1     | reference                  | 1     |
| II                       | 282                        | 1.989 (1.041-3.798) | 0.037 | 1.766 (0.710-4.391) | 0.221 |
| III                      | 310                        | 1.774 (0.951-3.312) | 0.072 | 1.955 (0.858-4.455) | 0.111 |
| Unknown                  | 290                        | 1.742 (0.809-3.754) | 0.156 | 2.385 (0.842-6.752) | 0.102 |
| **Race**                 |                            |       |                            |       |
| White                    | 1051                       | 1     | reference                  | 1     |
|          |   |                |     |                |     |
|----------|---|----------------|-----|----------------|-----|
| Black    | 173| 1.402(0.731-2.689) | 0.310| 1.056(0.410-2.720) | 0.911|
| Other    | 163| 0.727(0.330-1.601) | 0.428| 0.799(0.310-2.057) | 0.642|

| Age At Diagnosis(yr) | ≤60 | 844 | 1reference | 1reference |
|----------------------|-----|-----|------------|------------|
| ≥60                  | 543 | 1.866(1.192-2.921) | 0.006 | 1.998(1.107-3.803) | 0.022|

Univariate analysis of variables with P <0.1 then further analysis by multivariate cox regression model.

* Overlapping lesion of pancreas
† Pancreatic duct, other specified parts of pancreas.
† No lymph nodes were detected during surgery.
‡ Asian/American Indian/Alaska Native/Pacific Islander.

Table 6 and 7 not available with this version

**Figures**
Figure 1

Exclusion criteria and study design
Figure 2

Comparison of Long-term survival between different surgical procedures for G1 pNETs with diameter ≤4cm. A(CSS of different operations) and B(OS of different operations).
Figure 3

Comparison of Long-term survival between different surgical procedures for G2 pNETs with diameter ≤4cm. A(CSS of different operations) B(OS of different operations).